Omnicell Inc. (OMCL)
What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?
Shares of Omnicell OMCL have rallied 52.6% over the past year, significantly outperforming the industry's 20.8% fall and the S&P 500 composite's 23.9% gain.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Do Options Traders Know Something About Omnicell Stock We Don't?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble
Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Omnicell Stock a Smart Addition to Your Portfolio Now?
OMCL rides on SaaS growth, Autonomous Pharmacy adoption and expansion plans, but rising costs and competition could test its momentum.
Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omnicell (OMCL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
